

Biofoundry Automation and Industrial Biotechnology: Rethinking Scalable Biological Manufacturing

Shalamar Armstrong

Professor Purdue University

Abstract

Biofoundries are emerging as highly automated research and manufacturing environments that integrate synthetic biology, robotics, artificial intelligence, high-throughput experimentation and advanced analytical technologies to accelerate the design and production of biological products. Their development is transforming industrial biotechnology from predominantly manual laboratory workflows into increasingly automated, data-driven and scalable manufacturing systems. This paper examines the role of biofoundry automation in enabling scalable biological manufacturing, with particular emphasis on design–build–test–learn (DBTL) cycles, robotic laboratory systems, automated strain engineering, high-throughput screening, bioprocess optimisation, artificial intelligence and digital infrastructure. The study proposes an integrated biofoundry framework connecting biological design, automated construction, experimental testing, machine-learning-based analysis and iterative optimisation. Applications across sustainable chemicals, alternative proteins, pharmaceuticals, enzymes, biomaterials, biofuels and agricultural biotechnology are discussed. The paper also evaluates major barriers to industrial deployment, including biological variability, automation interoperability, process scale-up, data standardisation, contamination control, equipment costs and regulatory requirements. A central argument is that successful biofoundries should not be viewed merely as automated laboratories but as integrated biological engineering platforms capable of connecting research discovery with scalable manufacturing. The convergence of robotics, synthetic biology and artificial intelligence could enable more rapid design cycles, reduced experimental costs, improved process reproducibility and greater flexibility in biological production. However, achieving industrial-scale impact requires overcoming the gap between high-throughput laboratory experimentation and reliable commercial bioprocessing. Future biofoundries are likely to incorporate increasingly autonomous experimentation, digital twins, machine-learning-driven optimisation and distributed manufacturing capabilities. Such developments could establish a new model of industrial biotechnology in which biological systems are designed, tested, optimised and manufactured through increasingly automated and intelligent production ecosystems.

Keywords: Biofoundry, Industrial Biotechnology, Synthetic Biology, Laboratory Automation, Biological Manufacturing, Robotics, Design-Build-Test-Learn, Artificial Intelligence, Bioprocessing, High-Throughput Experimentation.

1. Introduction

Industrial biotechnology is undergoing a fundamental transformation.

Traditional biological manufacturing relies heavily on:

- Manual laboratory procedures.
- Human experimentation.
- Sequential optimisation.
- Small-scale screening.
- Limited experimental throughput.

Synthetic biology has changed the possibilities for engineering biological systems.

Researchers can now design:

- Microbial strains.
- Enzymes.
- Metabolic pathways.
- Genetic circuits.
- Cell-based production systems.

However, the number of possible biological designs can be enormous.

This creates a bottleneck.

The ability to design biological systems has increasingly outpaced the ability to build and experimentally evaluate them.

Biofoundries have emerged as a response to this challenge.

2. Concept of a Biofoundry

A biofoundry is an automated or semi-automated facility designed to accelerate biological engineering through high-throughput experimentation.

Its activities commonly include:

- DNA assembly.
- Genetic transformation.
- Cell cultivation.
- Screening.
- Analytical measurement.
- Data processing.
- Automated experimentation.

The core concept is:

Automate the biological engineering cycle to increase research speed and reproducibility.

3. From Laboratory Automation to Biofoundry Automation

Conventional laboratory automation often automates individual procedures.

For example:

- Liquid handling.
- Sample transfer.
- Plate reading.

Biofoundry automation seeks to automate entire workflows.

The distinction can be represented as:

Traditional Automation

Task → Automation

Versus

Biofoundry

Design → Build → Test → Analyse → Learn → Redesign

The second approach treats automation as an integrated scientific system.

4. The Design–Build–Test–Learn Cycle

The DBTL cycle forms the foundation of modern biological engineering.

Design

Computational systems generate biological designs.

Build

Robotic platforms construct biological systems.

Test

Automated systems measure biological performance.

Learn

AI and statistical models analyse results.

The cycle then begins again.

5. Design Phase

The design stage may involve:

- Genome engineering.
- Pathway design.
- Promoter selection.
- Enzyme engineering.
- Protein design.

- Metabolic optimisation.
- AI systems can evaluate large numbers of possible biological configurations.

6. Build Phase

The build stage converts computational designs into physical biological systems.

Automated equipment can perform:

- DNA assembly.
- Cloning.
- Transformation.
- Culture preparation.
- Sample preparation.

Robotic systems can execute hundreds or thousands of operations with consistent protocols.

7. Test Phase

The test stage measures biological performance.

Possible measurements include:

- Growth rate.
- Product concentration.
- Enzyme activity.
- Metabolite levels.
- Protein expression.
- Cellular phenotype.

High-throughput technologies allow many biological designs to be evaluated simultaneously.

8. Learn Phase

The learn stage converts experimental results into new biological knowledge.

Machine-learning systems can identify:

- Important variables.
- Relationships between genotype and phenotype.
- Optimal conditions.
- Unexpected biological interactions.

These findings inform the next design cycle.

9. Biofoundry Automation Architecture

A scalable biofoundry can be organised into several layers.

Layer 1 — Computational Design

AI and biological modelling.

Layer 2 — Automated Construction

Robotic DNA and strain engineering.

Layer 3 — High-Throughput Experimentation

Automated cultivation and screening.

Layer 4 — Analytical Measurement

Sensors and analytical instruments.

Layer 5 — Data Infrastructure

Laboratory information and data systems.

Layer 6 — AI Optimisation

Machine-learning-based decision-making.

10. Robotic Laboratory Infrastructure

Robotics is central to biofoundry automation.

Typical systems may include:

- Robotic arms.
- Automated liquid handlers.
- Plate handlers.
- Incubators.
- Centrifuges.
- Automated imaging systems.
- High-throughput analytical instruments.

These systems can operate continuously with limited human intervention.

11. Automated Liquid Handling

Liquid handling is one of the most repetitive laboratory tasks.

Automated platforms can:

- Dispense reagents.
- Transfer samples.
- Prepare dilution series.
- Construct assay plates.
- Perform serial operations.

This can improve throughput and reduce manual variability.

12. Automated Cell Culture

Biological manufacturing depends on maintaining appropriate cellular conditions.

Automated systems can control:

- Temperature.
- Agitation.
- Oxygen.
- Nutrient availability.
- Sampling frequency.

Such systems can provide consistent experimental conditions.

13. High-Throughput Screening

A major advantage of biofoundries is the ability to evaluate many biological designs simultaneously.

Instead of:

10 designs → manual testing

the system may enable:

Hundreds or thousands of designs → automated testing

This increases the exploration of biological design space.

14. Artificial Intelligence in Biofoundries

AI can support nearly every stage of the DBTL cycle.

Applications include:

- Sequence design.
- Protein engineering.
- Experimental optimisation.
- Image analysis.
- Metabolic modelling.
- Process control.

The combination of AI and automation creates an increasingly intelligent biological engineering environment.

15. Machine Learning for Strain Engineering

Microbial strains can be engineered to produce valuable compounds.

Machine-learning models can analyse relationships between:

Genotype → Metabolic State → Phenotype → Product Yield

This can help identify promising genetic modifications.

16. Metabolic Engineering

Industrial microorganisms can be engineered to produce:

- Organic acids.

- Amino acids.
- Vitamins.
- Enzymes.
- Biofuels.
- Pharmaceuticals.
- Specialty chemicals.

Biofoundries can accelerate the optimisation of metabolic pathways.

17. Enzyme Engineering

Enzymes are important industrial biocatalysts.

Their properties can be improved through:

- Directed evolution.
- Protein engineering.
- Computational design.
- High-throughput screening.

Automated platforms can evaluate large numbers of enzyme variants.

18. Protein Engineering

AI models can propose protein sequences with potentially improved:

- Stability.
- Activity.
- Selectivity.
- Solubility.

Biofoundries can experimentally test these designs at high throughput.

This creates an AI-guided protein-engineering loop.

19. Sustainable Chemical Manufacturing

Biological systems can potentially replace petroleum-derived chemical processes.

Biofoundries can support development of biological production systems for:

- Bioplastics.
- Organic acids.
- Specialty chemicals.
- Industrial solvents.
- Sustainable materials.

20. Alternative Proteins

Industrial biotechnology is increasingly exploring biological production of alternative proteins.

Biofoundries can support:

- Protein design.

- Microbial production.
- Fermentation optimisation.
- Taste and texture development.
- Nutritional optimisation.

High-throughput experimentation can accelerate candidate evaluation.

21. Pharmaceutical Biotechnology

Biofoundries can support pharmaceutical research and manufacturing through:

- Therapeutic protein engineering.
- Vaccine development.
- Enzyme production.
- Microbial metabolite production.
- Cell-line engineering.

Automation can reduce the time required for iterative optimisation.

22. Cell and Gene Therapy

Cell-based therapies require complex biological processes.

Automated systems can support:

- Cell culture.
- Genetic modification.
- Quality testing.
- Process monitoring.

However, clinical manufacturing requires strict validation and regulatory control.

23. Biopharmaceutical Manufacturing

Biofoundries can contribute to upstream bioprocess development.

Key variables include:

- Cell density.
- Nutrient concentration.
- Temperature.
- pH.
- Oxygen transfer.
- Feeding strategy.

AI-based optimisation can help identify favourable process conditions.

24. Fermentation Optimisation

Fermentation is central to industrial biotechnology.

Automated platforms can vary:

- Carbon sources.
- Nitrogen sources.

- Temperature.
- pH.
- Agitation.
- Oxygen supply.

Machine-learning models can identify relationships between these variables and product yield.

25. From Microplates to Industrial Bioreactors

A critical challenge is scaling from laboratory experiments to industrial production.

A result observed in a small microplate does not necessarily translate directly to a large bioreactor.

Differences can occur in:

- Oxygen transfer.
- Mixing.
- Heat transfer.
- Nutrient gradients.
- Shear stress.

Therefore, scale-up must be incorporated into biofoundry workflows.

26. Digital Twins for Biomanufacturing

Digital twins can provide computational representations of biological production systems.

A digital twin may simulate:

- Bioreactor conditions.
- Cell growth.
- Metabolic behaviour.
- Product formation.

Real-time experimental data can update the model.

This creates:

Physical Bioprocess ↔ Digital Model

27. Autonomous Bioprocess Optimisation

Future systems may continuously adjust process parameters.

The workflow becomes:

Measure → Predict → Adjust → Measure

This could improve:

- Yield.
- Productivity.
- Energy efficiency.
- Resource utilisation.

28. Data Infrastructure

Biofoundries generate large volumes of data.

These may include:

- DNA sequences.
- Experimental parameters.
- Sensor readings.
- Images.
- Analytical measurements.
- Sample metadata.

A robust data infrastructure is therefore essential.

29. FAIR Data Principles

Biofoundry data should ideally follow FAIR principles:

Findable

Accessible

Interoperable

Reusable

Standardised metadata and data formats are critical for achieving this goal.

30. Laboratory Information Management

Laboratory Information Management Systems can connect:

- Samples.
- Experiments.
- Instruments.
- Researchers.
- Results.

Integration with robotic platforms enables automated experiment tracking.

31. Interoperability

Different laboratory instruments often use different software and communication standards.

Interoperability challenges can limit automation.

Future biofoundries require standardised interfaces connecting:

Robots + Instruments + Software + Databases + AI

32. Biofoundry as a Manufacturing Platform

A mature biofoundry should not be viewed only as a research facility.

It can function as an integrated platform connecting:

Biological Design → Process Development → Scale-Up → Manufacturing

This creates a bridge between synthetic biology research and industrial production.

33. Distributed Biofoundries

Future biological manufacturing could become increasingly distributed.

Different biofoundries could specialise in:

- Protein engineering.
- Microbial strain development.
- Cell engineering.
- Biomaterials.
- Fermentation optimisation.

Digital platforms could connect these facilities.

34. Economic Benefits

Biofoundry automation may reduce:

- Experimental labour.
- Development time.
- Material waste.
- Repetitive procedures.

It may also increase:

- Experimental throughput.
- Reproducibility.
- Data generation.
- Innovation speed.

35. Sustainability Benefits

Biological manufacturing can potentially reduce dependence on fossil resources.

Biofoundries can contribute by optimising:

- Feedstock utilisation.
- Energy consumption.
- Product yields.
- Waste reduction.

However, biological production is not automatically sustainable.

Life-cycle analysis remains essential.

36. Biosafety

Increasing automation also introduces biosafety considerations.

Biofoundries must manage:

- Biological containment.
- Automated handling risks.
- Contamination.
- Unintended biological modifications.
- Access controls.

Safety systems should be incorporated into facility architecture.

37. Biosecurity

Advanced biological design technologies could potentially be misused.

Therefore, automated biofoundries require safeguards such as:

- Sequence screening.
- Access controls.
- Monitoring.
- Secure data systems.
- Institutional oversight.

38. Regulatory Challenges

Industrial biotechnology must comply with regulatory requirements.

These may involve:

- Product safety.
- Manufacturing consistency.
- Environmental impact.
- Genetic modification.
- Quality control.

Automated systems must therefore generate traceable and auditable records.

39. Quality Control

Automated manufacturing can improve consistency, but biological systems naturally exhibit variability.

Quality-control systems should monitor:

- Genetic stability.
- Product purity.
- Biological activity.
- Contamination.
- Batch consistency.

40. Human Expertise

Automation does not eliminate the need for scientists.

Researchers remain important for:

- Defining objectives.
- Interpreting biological mechanisms.
- Designing constraints.
- Validating results.
- Managing unexpected outcomes.

The future model is therefore likely to be human-guided automation rather than fully independent biological production.

41. Proposed Integrated Biofoundry Framework


The proposed model contains eight components:

1. Computational Design
2. AI-Based Prediction
3. Automated Biological Construction
4. High-Throughput Experimentation
5. Automated Measurement
6. Data Integration
7. Machine-Learning Optimisation
8. Scale-Up and Manufacturing

The system continuously cycles through these stages.

42. Experimental Workflow

A representative workflow is:



43. Evaluation Metrics

Category	Example Metrics
Throughput	Experiments/day
Automation	Percentage of automated tasks
Biological performance	Product yield
Process efficiency	Time per DBTL cycle
Data quality	Missing-data rate
Reproducibility	Experimental variance
Cost	Cost per successful design
Sustainability	Energy/material consumption
Scale-up	Laboratory-to-industrial performance

44. Research Questions

1. How can biofoundry automation improve the speed of biological engineering?
2. Which biological workflows provide the greatest benefits from automation?
3. How can AI improve DBTL cycle optimisation?
4. How can laboratory automation be integrated with industrial bioprocessing?
5. What are the main barriers to scaling biofoundry technologies?
6. How can digital twins improve biological manufacturing?
7. How can standardised data systems improve interoperability?
8. What level of autonomy is appropriate for industrial biofoundries?
9. How can biofoundries contribute to sustainable manufacturing?
10. What governance systems are necessary for safe and secure automated biotechnology?

45. Future Research Directions

Important future areas include:

- Fully integrated autonomous biofoundries.
- AI-designed microbial strains.
- Automated protein engineering.
- Self-optimising fermentation systems.
- Digital twins for biological production.
- Autonomous cell-line development.
- AI-controlled bioreactors.
- Distributed biofoundry networks.
- Automated quality control.
- Sustainable biological manufacturing.

46. Strategic Recommendations

Industrial biotechnology organisations should:

1. Develop modular automation architectures.
2. Adopt interoperable laboratory systems.
3. Integrate AI with DBTL workflows.
4. Establish robust biological data standards.
5. Build scalable automation platforms.
6. Incorporate digital twins into process development.
7. Develop automated quality-control systems.
8. Implement strong biosafety and biosecurity controls.
9. Establish regulatory-compliant data provenance.
10. Invest in interdisciplinary expertise combining biology, robotics, AI and process engineering.

47. Discussion

Biofoundry automation represents a shift from conventional laboratory experimentation towards engineering-scale biological discovery.

The fundamental advantage is not simply that robots perform laboratory tasks faster.

The deeper transformation comes from connecting:

Design + Construction + Experimentation + Measurement + Data + Learning

within a single continuous system.

This creates the possibility of industrial biotechnology becoming increasingly analogous to automated engineering disciplines.

In conventional engineering, computer-aided design, simulation and automated manufacturing are closely connected.

Biofoundries are beginning to establish a comparable model for biological systems:

**Computational Biological Design → Automated Construction → Automated Testing →
Data-Driven Optimisation**

This could dramatically expand the number of biological systems that researchers can explore.

48. Rethinking Scalable Biological Manufacturing

The traditional manufacturing model often begins with a biological process that has already been optimised through extensive experimentation.

Biofoundries could change this approach by integrating discovery and manufacturing development.

Instead of:

Research → Optimisation → Manufacturing

the future model could become:

Continuous Design → Continuous Experimentation → Continuous Optimisation → Adaptive Manufacturing

Such systems could make biological manufacturing more flexible and responsive.

49. Conclusion

Biofoundry automation represents an important development in industrial biotechnology.

By combining synthetic biology, robotics, artificial intelligence, high-throughput experimentation and advanced data infrastructure, biofoundries can transform biological engineering from a relatively manual process into an increasingly automated and scalable discipline.

The DBTL framework provides the foundation for this transformation.

Design → Build → Test → Learn → Redesign

When integrated with AI, the cycle can become increasingly predictive and adaptive.

Potential applications extend across:

- Pharmaceuticals.
- Alternative proteins.
- Sustainable chemicals.
- Enzymes.
- Biomaterials.
- Biofuels.
- Agricultural biotechnology.

However, major challenges remain, particularly around scale-up, biological variability, interoperability, data management, biosafety, biosecurity and regulatory compliance.

The future of biofoundries is therefore unlikely to be defined simply by more laboratory robots.

Instead, the major transformation will come from creating intelligent biological manufacturing ecosystems in which computational design, automated experimentation, machine learning and industrial bioprocessing operate as an integrated system.

The emerging paradigm can be summarised as:

AI + Synthetic Biology + Robotics + High-Throughput Experimentation + Bioprocess Engineering → Scalable Biological Manufacturing

Such an ecosystem could provide the technological foundation for a more flexible, sustainable and data-driven bioeconomy.

References

1. Hillson, N., Caddick, M. X., Cai, Y., et al. (2019). Building a global alliance of biofoundries. *Nature Communications*, 10, 2040.
2. Chao, R., Mishra, S., Si, T., & Zhao, H. (2017). Engineering biological systems using automated biofoundries. *Metabolic Engineering*, 42, 98–108.
3. Hamedirad, M., Weisberg, S., Choi, J. M., et al. (2019). Towards a fully automated algorithm driven platform for biosystems design. *Nature Communications*, 10, 5150.
4. Carbonell, P., Radivojevic, T., & García Martín, H. (2019). Opportunities at the intersection of synthetic biology, machine learning and automation. *Nature Communications*, 10, 3076.
5. Nielsen, A. A. K., Der, B. B., Shin, J., et al. (2016). Genetic circuit design automation. *Science*, 352(6281), aac7341.
6. Casini, A., Chang, F. Y., Eluere, R., et al. (2018). A pressure-based DNA assembly method for synthetic biology. *Nature Communications*, 9, 1745.
7. Appleton, E., Madsen, C., Roehner, N., & Densmore, D. (2017). Design automation in synthetic biology. *Cold Spring Harbor Perspectives in Biology*, 9(9), a023978.
8. Nielsen, A. A. K., & Keasling, J. D. (2016). Engineering cellular metabolism. *Cell*, 164(6), 1185–1197.
9. Cravens, A., Payne, J., & Smolke, C. D. (2019). Synthetic biology strategies for microbial biosynthesis of plant natural products. *Nature Communications*, 10, 2142.
10. Lee, S. Y., Kim, H. U., Chae, T. U., et al. (2019). A comprehensive metabolic map for production of bio-based chemicals. *Nature Catalysis*, 2, 18–33.
11. Nielsen, J., & Keasling, J. D. (2016). Engineering cellular metabolism. *Cell*, 164(6), 1185–1197.
12. Silverman, A. D., Karim, A. S., & Jewett, M. C. (2020). Cell-free gene expression systems for metabolic engineering and biomanufacturing. *Biotechnology and Bioengineering*, 117(8), 2765–2777.
13. Tisato, V., et al. (2020). Synthetic biology and industrial biotechnology: Emerging opportunities and challenges. *Current Opinion in Biotechnology*.
14. Carbonell, P., Wong, J., Swainston, N., & Takano, E. (2018). Ranking the biosynthetic potential of genomic and metagenomic libraries. *Nature Communications*, 9, 1340.
15. Burgard, A. P., Pharkya, P., & Maranas, C. D. (2003). Optknock: A bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. *Biotechnology and Bioengineering*, 84(6), 647–657.